Acute Porphyria Drugs

J07BK03 - Zoster, Purified Antigen

Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the Purified antigen Zoster vaccine, no porphyrinogenic effects are expected.
Chemical description
Purified antigen.
Therapeutic characteristics
Indicated for protection against shingles (herpes zoster) and post-herpetic neuralgia in adults over the age of 50 or in adult over the age of 18 who are at increaced risk of herpes zoster. It is administered by intramuscular injections.
Metabolism and pharmacokinetics
Vaccines are not metabolized by the cytochrome P450 system.
Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BK or go back.
References
# Citation details PMID
*Government bodies
1. European Medicines Agency (EMA). SmPC Shingrix.
2. Norwegian institute of public health. Vaccines and vaccination.

Tradenames

Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Shingrix Vaccines
In cooperation with Ipnet
© NAPOS 2025
An unhandled error has occurred. Reload 🗙